David Dale

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia
    D C Dale
    Divisions of Hematology and Medical Genetics, Department of Medicine and the Markey Molecular Medicine Center, University of Washington School of Medicine, Seattle, WA, USA
    Blood 96:2317-22. 2000
  2. pmc Advances in the treatment of neutropenia
    David C Dale
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Curr Opin Support Palliat Care 3:207-12. 2009
  3. ncbi request reprint Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
    W Conrad Liles
    Department of Medicine, University of Washington, HSB AA 522, Box 356422, Seattle, WA 98195
    Blood 102:2728-30. 2003
  4. ncbi request reprint Neutrophil biology and the next generation of myeloid growth factors
    David C Dale
    Department of Medicine, University of Washington, Seattle, WA 98195 6422, USA
    J Natl Compr Canc Netw 7:92-8. 2009
  5. doi request reprint The phagocytes: neutrophils and monocytes
    David C Dale
    Department of Medicine, University of Washington School of Medicine, Seattle A98195, USA
    Blood 112:935-45. 2008
  6. ncbi request reprint Alpha Omega Alpha: encouraging excellence in medicine for more than a century
    David C Dale
    Alpha Omega Alpha, 525 Middlefield Road, Suite 130, Menlo Park, California 94025, USA
    Pharos Alpha Omega Alpha Honor Med Soc 65:4-21. 2002
  7. ncbi request reprint Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry
    David C Dale
    Department of Medicine, Box 356422, University of Washington, Seattle, WA 98195, USA
    Am J Hematol 72:82-93. 2003
  8. ncbi request reprint Poor prognosis in elderly patients with cancer: the role of bias and undertreatment
    David C Dale
    University of Washington, Seattle, Washington 98195, USA
    J Support Oncol 1:11-7. 2003
  9. ncbi request reprint Colony-stimulating factors for the management of neutropenia in cancer patients
    David C Dale
    Department of Medicine, University of Washington, Seattle, Washington 98195 6422, USA
    Drugs 62:1-15. 2002
  10. ncbi request reprint Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials
    David C Dale
    University of Washington, Department of Medicine, Box 356422, HSB, Room AA522, 1959 NE Pacific, Seattle, WA 98195 6422, USA
    J Natl Compr Canc Netw 1:440-54. 2003

Research Grants

Detail Information

Publications56

  1. ncbi request reprint Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia
    D C Dale
    Divisions of Hematology and Medical Genetics, Department of Medicine and the Markey Molecular Medicine Center, University of Washington School of Medicine, Seattle, WA, USA
    Blood 96:2317-22. 2000
    ..This study indicates that mutations of the gene encoding neutrophil elastase are probably the most common cause for severe congenital neutropenia as well as the cause for sporadic and autosomal dominant cyclic neutropenia...
  2. pmc Advances in the treatment of neutropenia
    David C Dale
    Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Curr Opin Support Palliat Care 3:207-12. 2009
    ..The present review updates treatment of neutropenia from articles published from January 2008 through April 2009...
  3. ncbi request reprint Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
    W Conrad Liles
    Department of Medicine, University of Washington, HSB AA 522, Box 356422, Seattle, WA 98195
    Blood 102:2728-30. 2003
    ..AMD3100 was well tolerated and caused only mild, transient toxicity. These findings suggest potential clinical application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation...
  4. ncbi request reprint Neutrophil biology and the next generation of myeloid growth factors
    David C Dale
    Department of Medicine, University of Washington, Seattle, WA 98195 6422, USA
    J Natl Compr Canc Netw 7:92-8. 2009
    ..Advances in neutrophil biology coupled with better understanding and development of myeloid growth factors offer great promise for improving the care of patients with cancer and many other disorders...
  5. doi request reprint The phagocytes: neutrophils and monocytes
    David C Dale
    Department of Medicine, University of Washington School of Medicine, Seattle A98195, USA
    Blood 112:935-45. 2008
    ..Over the last 50 years, many genetic and molecular disorders of phagocytes have been identified, leading to improved diagnosis and treatment of conditions which predispose patients to the risk of recurrent fevers and infectious diseases...
  6. ncbi request reprint Alpha Omega Alpha: encouraging excellence in medicine for more than a century
    David C Dale
    Alpha Omega Alpha, 525 Middlefield Road, Suite 130, Menlo Park, California 94025, USA
    Pharos Alpha Omega Alpha Honor Med Soc 65:4-21. 2002
  7. ncbi request reprint Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry
    David C Dale
    Department of Medicine, Box 356422, University of Washington, Seattle, WA 98195, USA
    Am J Hematol 72:82-93. 2003
    ..The risk of leukemia, osteoporosis, other potentially adverse events, and pregnancy outcome need to be further evaluated with continuing long-term observations...
  8. ncbi request reprint Poor prognosis in elderly patients with cancer: the role of bias and undertreatment
    David C Dale
    University of Washington, Seattle, Washington 98195, USA
    J Support Oncol 1:11-7. 2003
    ..Establishing age-based standards for cancer care will become more important as the US population ages...
  9. ncbi request reprint Colony-stimulating factors for the management of neutropenia in cancer patients
    David C Dale
    Department of Medicine, University of Washington, Seattle, Washington 98195 6422, USA
    Drugs 62:1-15. 2002
    ....
  10. ncbi request reprint Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials
    David C Dale
    University of Washington, Department of Medicine, Box 356422, HSB, Room AA522, 1959 NE Pacific, Seattle, WA 98195 6422, USA
    J Natl Compr Canc Netw 1:440-54. 2003
    ..We recommend that standard procedures for documenting and reporting hematologic toxicity and dose intensity in cancer chemotherapy trials be required for publication of chemotherapy trials...
  11. ncbi request reprint Recertification in internal medicine - the American experience
    David C Dale
    American College of Physicians, Seattle, WA, USA
    Ann Acad Med Singapore 36:894-7. 2007
    ..MOC has been well received by professional organisations, but there are areas of controversy. It has been accepted as an important way for internists to assure quality of practice and currency of medical information...
  12. doi request reprint Cyclic and chronic neutropenia
    David C Dale
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Cancer Treat Res 157:97-108. 2011
    ..Ten to thirty percent of severe congenital neutropenia patients evolve to develop acute myeloid leukemia, necessitating careful clinical monitoring...
  13. ncbi request reprint Optimizing the management of chemotherapy-induced neutropenia
    David C Dale
    Department of Medicine, University of Washington, Seattle, WA 98195, USA
    Clin Adv Hematol Oncol 1:679-84. 2003
    ..The availability of pegfilgrastim, a sustained-duration G-CSF that has benefits comparable to those of filgrastim with a single injection per chemotherapy cycle, has simplified CSF therapy...
  14. ncbi request reprint Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors
    David Dale
    Department of Medicine, University of Washington, 1959 NE Pacific St, Box 356422, Seattle, WA 98195, USA
    Semin Oncol 30:3-9. 2003
    ..This review summarizes the clinical consequences of CIN and describes current best practices for the management of patients at risk for CIN...
  15. ncbi request reprint Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist
    W Conrad Liles
    Department of Medicine, University of Washington, Seattle, Washington 98195, USA
    Transfusion 45:295-300. 2005
    ..AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects...
  16. ncbi request reprint Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
    Michelle Shayne
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Cancer 110:1611-20. 2007
    ..This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients...
  17. ncbi request reprint Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and inte
    Kai Hubel
    Department of Medicine, University of Washington, Seattle, Washington, USA and Department I of Internal Medicine, University of Cologne, Cologne, Germany
    J Infect Dis 185:1490-501. 2002
    ..However, variable therapeutic efficacy has been reported in clinical trials conducted to date. This review summarizes the current status of the use of G-CSF, GM-CSF, M-CSF, and IFN-gamma in the treatment of infectious diseases...
  18. ncbi request reprint Molecular basis and therapy of disorders associated with chronic neutropenia
    Steven M Stein
    Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356422, Seattle, WA 98195, USA
    Curr Allergy Asthma Rep 3:385-8. 2003
    ..Granulocyte colony stimulating factor (G-CSF) is effective treatment for several of these conditions. Through better understanding of these disorders, we anticipate that better treatments will be found in the future...
  19. ncbi request reprint Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemia
    Andrew A G Aprikyan
    Department of Medicine, University of Washington School of Medicine, Seattle, Wash, USA
    Exp Hematol 31:372-81. 2003
    ..Furthermore, our results suggest that acquired G-CSFR mutations may initiate signaling events that override the pro-apoptotic effect of mutant NE in primitive progenitor cells, resulting in an expansion of the abnormal AML clone...
  20. ncbi request reprint Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF delivery
    Ofer Yanay
    Department of Pediatrics, MS 356320, University of Washington, Seattle, WA 98195, USA
    Blood 102:2046-52. 2003
    ..Thus, intramuscular administration of lentivirus encoding G-CSF provided sustained therapeutic levels of neutrophils, suggesting this approach may be applied for long-term treatment of patients with cyclic and other neutropenias...
  21. ncbi request reprint Cloning and sequencing of the canine neutrophil elastase cDNA
    Louis J Katen
    Division of Pediatric Genetics, Department of Pediatrics, HSB RR244 Box 356320, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA
    DNA Seq 13:221-3. 2002
    ..Towards the validation of this animal model, we have cloned and sequenced the canine NE cDNA from a normal dog...
  22. ncbi request reprint Mutant elastase in pathogenesis of cyclic and severe congenital neutropenia
    Andrew A G Aprikyan
    Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 6422, USA
    J Pediatr Hematol Oncol 24:784-6. 2002
    ..We hypothesize that abnormal processing and subcellular localization of mutant NE might predetermine the etiology of cyclic or severe congenital neutropenia...
  23. ncbi request reprint Updated ASCO recommendations for the use of white blood cell growth factors
    David C Dale
    University of Washington Medical Center, Seattle, WA 98195, USA
    Clin Adv Hematol Oncol 4:664-6. 2006
  24. ncbi request reprint Cyclic neutropenia
    David C Dale
    Department of Medicine, and the Severe Chronic Neutropenia International Registry, University of Washington, Seattle, WA 98195 6422, USA
    Semin Hematol 39:89-94. 2002
    ..Leukemic transformation is not a recognized risk for cyclic neutropenia, with or without treatment with G-CSF...
  25. ncbi request reprint Introduction: severe chronic neutropenia
    David C Dale
    Department of Medicine, University of Washington, Seattle, WA 98195 6422, USA
    Semin Hematol 39:73-4. 2002
  26. pmc Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia
    Jun Xia
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Br J Haematol 147:535-42. 2009
    ..In patients without ELANE mutations, other known SCN-associated gene mutations will be found rarely and genotyping can be guided by the clinical features of each patient...
  27. ncbi request reprint An adult dog with cyclic neutropenia treated by lentivirus- mediated delivery of granulocyte colony-stimulating factor
    Ofer Yanay
    Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
    Hum Gene Ther 17:464-9. 2006
    ..These studies show that an adult animal is responsive long-term to lentivirus-mediated G-CSF delivery, suggesting this approach may be applied for treatment of adult patients with cyclic and other neutropenias...
  28. doi request reprint Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy
    Michelle Shayne
    Department of Medicine, University of Rochester and the James P Wilmot Cancer Center, Rochester, NY, USA
    Cancer 115:5319-28. 2009
    ..This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients treated with curative intent in the community setting...
  29. pmc Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
    Daniel C Link
    Division of Oncology, Department of Medicine, Washington University, St Louis, MO 63110, USA
    Blood 110:1648-55. 2007
    ..These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukemogenesis...
  30. ncbi request reprint Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor
    Kai Hubel
    Department of Medicine, University of Washington, WA 98195 8050, USA
    Transfusion 45:1876-89. 2005
    ..10 degrees C) with maintenance of functional properties in vitro and in vivo...
  31. ncbi request reprint Neutropenia: causes and consequences
    Laurence Boxer
    Department of Pediatrics, University of Washington, Seattle, WA 98195 6422, USA
    Semin Hematol 39:75-81. 2002
    ..Most severely neutropenic patients have a history of oral ulcers and inflammation and recurrent skin infections. Examination of a bone marrow aspirate and/or biopsy and cytogenetic testing are primary for diagnostic evaluation...
  32. ncbi request reprint Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors
    Kai Hubel
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Transfusion 42:1414-21. 2002
    ....
  33. ncbi request reprint Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy
    Jennifer J Griggs
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 25:277-84. 2007
    ..The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in the adjuvant treatment of breast cancer...
  34. ncbi request reprint Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
    Nicole M Kuderer
    James P Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 106:2258-66. 2006
    ..The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mortality and prolonged hospitalization in cancer patients with FN...
  35. pmc Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist
    Hal E Broxmeyer
    Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Exp Med 201:1307-18. 2005
    ..These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization...
  36. pmc Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia
    Philip S Rosenberg
    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
    Br J Haematol 140:210-3. 2008
    ..96). Patients with either mutant or wild-type ELA2 should be followed closely for leukaemic transformation...
  37. ncbi request reprint Advances in the use of colony-stimulating factors for chemotherapy-induced neutropenia
    David C Dale
    J Support Oncol 3:39-41. 2005
  38. pmc The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy
    Philip S Rosenberg
    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852 7244, USA
    Blood 107:4628-35. 2006
    ..Risk of MDS/AML may be similar in SDS and SCN. In less-responsive SCN patients, early hematopoietic stem cell transplantation may be a rational option...
  39. ncbi request reprint Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Leuk Lymphoma 44:2069-76. 2003
    ..13, 95% CI: 1.20-3.76). Such a model may permit the identification of patients at greatest risk of febrile neutropenia and, therefore, candidates for the selective prophylactic use of the hematopoietic growth factors...
  40. ncbi request reprint Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells
    Goran Carlsson
    Childhood Cancer Research Center, Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden
    Blood 103:3355-61. 2004
    ..In sum, these studies establish a role for mitochondria-dependent apoptosis in the pathogenesis of Kostmann syndrome and yield a tentative explanation for the beneficial effect of growth factor administration in these patients...
  41. ncbi request reprint Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management
    Jeffrey Crawford
    Divisions of Oncology and Hematology, Duke University Medical Center, PO Box 25178 Morris Building, Durham, NC 27710 0001, USA
    Cancer 100:228-37. 2004
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  42. ncbi request reprint Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review
    Nicole M Kuderer
    University of Rochester School of Medicine and Dentistry, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Clin Oncol 25:3158-67. 2007
    ..Several RCTs have been published recently that investigate the impact of G-CSF on mortality and relative dose-intensity (RDI)...
  43. ncbi request reprint Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice
    Jeffrey Crawford
    Duke University, Durham, North Carolina, USA
    J Natl Compr Canc Netw 6:109-18. 2008
    ..Despite frequent planned reductions from standard RDI, the incidence of FN remains high in community oncology practice in the United States. Improved methods of pretreatment assessment of patient risk factors for neutropenia are needed...
  44. ncbi request reprint Myeloid growth factors clinical practice guidelines in oncology
    Jeffrey Crawford
    Duke Comprehensive Cancer Center, Duke University, Durham, NC, USA
    J Natl Compr Canc Netw 3:540-55. 2005
  45. ncbi request reprint Myeloid growth factors. Clinical practice guidelines in oncology
    Jeffrey Crawford
    J Natl Compr Canc Netw 5:188-202. 2007
  46. ncbi request reprint Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry
    Debra Wolff
    J Support Oncol 3:24-5. 2005
  47. ncbi request reprint Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern Sweden
    Goran Carlsson
    Department of Woman and Child Health, Karolinska University Hospital Solna, Stockholm, Sweden
    Haematologica 91:589-95. 2006
    ..Mutations in the neutrophil elastase gene (ELA-2) have previously been identified in patients with sporadic or autosomal dominant SCN...
  48. ncbi request reprint Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
    Michelle Shayne
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Breast Cancer Res Treat 100:255-62. 2006
    ..This retrospective study was undertaken to define risk factors for reductions in dose intensity of adjuvant chemotherapy in women with early stage breast cancer (ESBC)...
  49. ncbi request reprint Severe congenital neutropenia
    Karl Welte
    Department of Pediatric Hematology Oncology, Medical School Hannover, Hannover, Germany
    Semin Hematol 43:189-95. 2006
    ..Hematopoietic stem cell transplantation (HSCT) is still the only treatment available for patients who are refractory to G-CSF treatment...
  50. ncbi request reprint Update on the management of neutropenia
    David C Dale
    Clin Adv Hematol Oncol 4:187-9. 2006
  51. ncbi request reprint Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    J Clin Oncol 21:4524-31. 2003
    ..This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI)...
  52. ncbi request reprint Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutations
    Laurence A Boxer
    Divison of Pediatric Hematology Oncology, Department of Pediatrics, C S Mott Children s Hospital, University of Michigan, Ann Arbor, Michigan 48109 0238, USA
    J Pediatr 148:633-6. 2006
    ..To investigate cases of severe congenital neutropenia (SCN) to ascertain SCN inheritance after determining that the same sperm donor was used by 4 different families to impregnate mothers...
  53. ncbi request reprint Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy
    Matti S Aapro
    Clinique de Genolier, Genolier, Switzerland
    Support Care Cancer 14:1184-94. 2006
    ....
  54. ncbi request reprint Lineage-specific hematopoietic growth factors
    David C Dale
    N Engl J Med 355:526-7; author reply 527. 2006
  55. ncbi request reprint Achieving a high-performance health care system with universal access: what the United States can learn from other countries
    Jack A Ginsburg
    Ann Intern Med 148:55-75. 2008
    ..This caution notwithstanding, we have identified several approaches that have worked well for countries like ours and could probably be adapted to the unique circumstances in the United States...
  56. ncbi request reprint Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
    Jennifer J Griggs
    University of Rochester, Rochester, NY, USA
    J Clin Oncol 25:2522-7. 2007
    ..Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens...

Research Grants6

  1. Severe Chronic Neutropenia International Registry
    David Dale; Fiscal Year: 2007
    ..All of these efforts are directed toward improving understanding in the care of patients with severe neutropenia. ..
  2. MARROW REGULATION IN CYCLIC HEMATOPOIESIS
    David Dale; Fiscal Year: 2003
    ....